Dr. Mehmet Oz holds millions of dollars worth of shares in health insurance, fertility, pharmaceutical and vitamin companies ...

The world’s population is aging at an unprecedented pace. According to WHO’s October 2024 report, the number of people aged 60 and older surpassed children under five for the first time in 2020. By ...

There are three key reasons to avoid the blue-chip $68 billion SCHD ETF, including better alternatives and lower yield.

AbbVie’s CEO Richard Gonzalez took a huge bet that Rova-T would be the next big thing in oncology. Rova-T had a convincing-looking mechanism of action, consisting of an antibody that locks onto ...

Defense Secretary Pete Hegseth has ordered senior military and Defense Department officials to draw up plans to cut 8 percent ...

Mehmet Oz, Trump's nominee to lead the Centers for Medicare and Medicaid Services, pledged to divest his investments in ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Auto approaches have had the most success of any cell therapies to date, but they’re complicated to administer and come with huge price tags ... cell therapy hits the big leagues.

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

California Giant Berry Farms shared the availability of its GIANT Blueberries, large (20mm+) and flavorful berries with a new label design ...

Training starting up for the San Francisco Giants, the franchise will be hoping to improve in 2025. For the last number of years, the Giants have fallen on some hard times as a franchise. In seven of ...